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Abstract  
 
Background:: Statins reduce cardiovascular risk especially in patients with hypertension due to their 
concomitant blood pressure reducing effects. Prescribing generic statins minimizes cost and improves 
access. Aims: Ascertain current prescribing of statins in Nigeria and potential savings from the 
increased use of generics. Methods: Prospective study involving hypertensive patients attending 
University College Hospital, Ibadan, Nigeria. Results: 228 hypertensive patients received statins. 
Atorvastatin was the most prescribed statin, followed by simvastatin, rosuvastatin and finally 
fluvastatin. Prescribed doses were less than 1 defined daily dose in the majority, with high use of 
originators. Average monthly potential savings from increased prescribing of generics was US$2,635 
for atorvastatin and US$10578 for rosuvastatin. Conclusions: A shift towards increased prescribing 
generics is recommended to minimize costs 
 
Introduction 
 
Hypertension is a major public health concern with enormous financial implications to individuals, 
governments and third party payers [1-3]. It is a risk factor for development of cardiovascular 
diseases, which is a leading cause of morbidity and mortality worldwide [4]. The presence of elevated 
total and low density lipoprotein in hypertensive patients further increases cardiovascular risk [5]. 
Statins (3-hydroxy 3-methyl glutaryl co-enzyme A (HMG-COA) reductase inhibitors) are first-line 
treatment for patients with cardiovascular risk and elevated serum cholesterol [6-8] . Statins are 
particularly useful for treating hypercholesterolemia in hypertensive patient because of their 
concomitant blood pressure reducing effects [9-11]. These effects have been largely attributed to their 
reported ability to improve arterial compliance, increase bioavailability of nitric oxide, improve 
endothelial-dependent vasodilation and reduce levels of endothelin-1, which is a potent 
vasoconstrictor [12-15]. Down regulation in the expression of angiotensin type 1 (AT1) receptors, 
p22phox -a NADPH oxidase subunit, and a reduction of free radical release in the vasculature by statins 
also reduces blood pressure [16, 17]. Consequently, statins should be prescribed alongside 
medicines to treat hypertension to reduce morbidity and mortality in patients with cardiovascular 
disease including hypertension [8] . 
 
Recent studies have shown limited difference in the effectiveness of different statins at therapeutic 
doses, no difference in the effectiveness between generic and originator (brand name) statins and 
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successful switching of patients between higher priced patented and generic statins to save 
considerable resources without compromising care [18-21].  Cost considerations are increasingly 
important especially with the growing prevalence of non-communicable diseases including diabetes, 
hypertension, and obesity and generic statins priced as low as 2% to 4% of pre-patent loss prices in 
some countries  [3, 22-24] .  
 
Cost considerations are particularly important in Nigeria where over 90% of the population are not 
covered by any form of health insurance and out of pocket spending (OOP) can be as high as 62% of 
total healthcare expenditure [25-28]. Typically only medicines for patients with HIV/ AIDS are free of 
charge as these are provided by donors. All others are bought by patients (OOP) if they do not have 
access to health insurance. However, high patient co-payments potentially impact on available 
medicine choices as well as affecting long term compliance [29, 30].  
 
In Nigeria, the National Agency for Food and Drug Administration (NAFDAC) is the main regulatory 
body for medicines including generics [31[, and current regulations stipulate that prescriptions should 
be made using the international non-proprietary name (INN) [32], endorsing practices in other 
countries, e.g. Lithuania and the United Kingdom [22, 33]. However, there are no formal regulations 
for the pricing of generics in Nigeria unlike Europe [34, 35] , which has resulted in higher prices for 
generics in Nigeria compared with the UK, e.g. for generic SSRIs [36]. In addition, there are concerns 
with the quality of generics among physicians in Nigeria, especially locally produced generics, 
potentially impacting on their prescribing in practice [37]. There are also concerns with the doses of 
statins prescribed in the management of patients with cardiovascular disease, especially simvastatin, 
e.g. the average dose of simvastatin for secondary prevention in patients in Ireland was only 22mg 
with a number of other studies showing similar low doses of simvastatin being prescribed [38, 39].  
 
Consequently, there is a need to assess the level of prescribing of generic versus originator and 
patented statins in Nigeria, the doses prescribed as well as their costs, to ascertain the current 
rationality of the prescribing of statins in Nigeria. Any underdosing of statins needs to be urgently 
addressed as this VLJQLILFDQWO\LQFUHDVHVSDWLHQWV¶ULVNRIGHYHORSLQJ or progressing their 
cardiovascular disease with reduced cardioprotection [40]. In addition, putting them at risk for heart 
attack or stroke [41].The findings from the study will be used to suggest pertinent measures and 
initiatives that could be introduced in Nigeria to improve rational prescribing of statins. Alongside this, 
obtain lower costs for generic statins if this proves to be a concern. These are the multiple aims of this 
study. To the best of our knowledge, this is the first study in Nigeria to assess all these parameters.  
 
Method 
 
Hypertensive patients attending three out-patient clinics of the University College Hospital (UCH), 
Ibadan, South-west Nigeria between November 2011 and April 2012 were enrolled prospectively into 
the study after obtaining ethical approval from the hospital Institutional Ethics Review Board. 
Consecutive hypertensive patients with or without complications and co-morbidities attending the 
clinics, who had been diagnosed with high serum cholesterol levels, were enrolled into the study. 
3DWLHQWV¶GHPRJUDSKLFLQformation, prescribed statins grouped according to originator or generic, and 
prescribed doses were collected from their medical records after each clinic visit.  
 
The prescribed doses were subsequently compared with the defined daily dose (DDD) for each statin 
to assess potential underdosing, with '''VGHILQHGDVµthe average maintenance dose of a drug 
when used in its major indication in adults¶. This measure is recognised as the international standard 
to assess utilisation patterns within and between countries (42).Current DDDs were used in line with 
recommendations [42, 43]. This is similar to the methodology employed to assess current dosing of 
statins in other studies [38, 44]. 
 
The prices of medications at the time of prescription were obtained from the hospital pharmacy. 
Where there were omissions in the cost of any statin in the hospital price lists due to non-availability 
of the statins in hospital pharmacies, the costs of the statins from pharmacies near the hospital were 
used. This is under the assumption that patients will patronize nearby pharmacies where their 
prescribed medicines are currently unavailable in hospital pharmacies due to supply issues. Costs of 
prescribed statins were computed according to the strength prescribed, with the local currency (Naira) 
converted to US dollars at rates obtainable during study period i.e.(?160 per US$. These exchange 
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rates were chosen due to considerable changes in the conversion rates from Naira to US$ especially 
in recent times. As a result, factor out major shifts in exchange rates, potentially distorting the 
findings. Finally, a comparison was made between current statin prescribing and potential costs if 
there were 100% generic statin prescribing to determine the extent of potential cost savings from 
increasing prescribing of generics.  
 
A chi-squared analysis was performed for certain parameters, e.g. any differences in the prescribing 
of originators (brand named) medicines in male versus female physicians, with p <0.05 representing 
significance.   
 
Results 
 
Statins were prescribed to 228 patients enrolled into the study with males (106) constituting 46.5% of 
patients and females (122) 53.5%. 52 patients had heart-related diseases, 60 had diabetes, with 20 
having renal diseases. Most patients were aged between 50 and 70 years, with the ages ranging from 
33 to 85 years with a mean age of 60±10 years.  
 
Originator drugs were mostly prescribed (67%) among the statins except for simvastatin, which was 
prescribed by generic name only (Table 1).  
 
Table 1: Distribution of statins prescribed to hypertensive patients between November 2011 to April 
2012 (Brackets refer to the % of the total number of patients) 
 
 
Atorvastatin was the most prescribed statin, followed by simvastatin  and rosuvastatin  (Table 1), with 
fluvastatin the least prescribed statin. There was greater prescribing of originator statins among 
males, although the difference between the two groups was not statistically significant. Lovastatin and 
pravastatin were not included in this study as typically these two statins are not currently marketed in 
Nigeria and not stocked by the hospitals as not on the formulary. Physicians need a strong rationale 
for prescribing outside the current formulary.  
 
The prescribed doses were low compared to current DDDs. 13 patients were prescribed statins at 
doses greater than 1 DDD, whilst 45 prescriptions were at doses equal to 1 DDD and 167 patients 
were prescribed doses less than 1 DDD. The mean DDD was 0.66±0.33 with a range equal to 0.17 to 
2,67 DDDs (Males = 0.71±0.38 and Females = 0.63±0.29) (Table 2).   
 
  
Statin Dose per day (mg) 
 5 10 20 25 30 40 80 Missing Total 
M (%) F (%) All (%) 
Atorvastatin Originator 1 64 36 - 1 2 - 2 56 
(24.6) 
50 
(21.9) 
106 
(46.5) 
Generic - 18 3 - - - - - 9  (3.9) 12 
(5.3) 
21 (9.2) 
Fluvastatin Originator - - 5 - - - 2 - 1 (0.4) 6 (2.6) 7 (3.1) 
Generic - - 1 - - - - - 1 (0.4) 0 1 (0.4) 
Rosuvastatin Originator 36 3 1 - - - - - 22 
(9.6) 
18 
(7.9) 
40 
(19.5) 
 Generic 1 1 - - - - - - 0 2 (0.9) 2 (0.9) 
Simvastatin Generic 1 14 27 1 - 6 1 1 17 
(7.5) 
34 
(14.9) 
51 
(22.4) 
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Table 2: Comparison of prescribed daily dose of statins with daily defined doses among hypertensive 
patients between November 2011 to April 2012 (figures = % of the total number of patients) 
 
*DDD= Daily defined dose 
 
The total monthly costs for the statins were 86(?1,058,040) (Table 3). This was highest for 
atorvastatin as it was the most prescribed statin; however, fluvastatin was the most expensive statin 
 
Table 3 Total average statin costs per month in US$ and Naira and US$  
 
Statin Total monthly cost for all 
patients (US$ and N) 
Average monthly cost/ patient 
(US$ and N) 
Atorvastatin (? (?) 
Fluvastatin (? (?) 
Rosuvastatin (? (?) 
Simvastatn (? (?) 
All statins (? (? 
 
The differences in the total monthly cost of generics and originators for atorvastatin, fluvastatin and 
rosuvastatin (Table 3) reflect differences in their cost per patient (generic and originator) (Table 4) as 
well as the prescribed dose (Table 2). 
 
The average monthly costs of statins per mg per SDWLHQWYDULHGEHWZHHQ86(?) for 
VLPYDVWDWLQZKHUHRQO\JHQHULFVZHUHGLVSHQVHGWR86(?) for originator fluvastatin 
(Table 4). 
 
Table 4 ± Total monthly cost per patient and per mg for originator and generic statins in Naira and 
US$ 
 
 
Statin Total monthly cost of 
originators/mg/patient 
US$ (NGN) 
Total monthly cost of 
generics/mg/patient 
US$ (NGN) 
Atorvastatin 38.18 (6 109.50) 9.64 (1 542.90) 
Fluvastatin 73.13 (11 700.00) 16.88 (2 700.00) 
Rosuvastatin 35.30 (5 647.50) 13.36(2 137.50) 
Simvastatin - 11.08(1 772.00) 
 
As a result of the differences in the prices of generics and originators for the various statins (Table 4), 
the average potential savings per month from the total prescribing of generics at the ascertained 
prices for each statin (Table 4) to the 228 hypertensive patients with hypercholesterolemia was 
US(?IRUDWRUYDVWDWLQUS$1,058 ((?169 275.00) for rosuvastatin and U$276 (?4 
190.00) for fluvastatin (Figure 1). 
 
  
Statin and 
their DDD 
 <DDD (%) = DDD (%) >DDD (%) Missing 
(%) 
Total (%) 
Atorvastatin 
(20mg) 
Originator 65 (28.5) 36 (15.8) 3 (1.3) 2 (0.9) 106 (46.5) 
Generic 18 (7.9) 3 (1.3) - - 21 (9.2) 
Fluvastatin 
(60mg) 
Originator 5 (2.2) - 2 (0.9) - 7 (3.1) 
Generic 1 (0.4) - - - 1 (0.4) 
Rosuvastatin 
(10mg) 
Originator 36 (15.8) 3 (1.3) 1 (0.4) - 40 (17.5) 
Generic 1 (0.4) 1 (0.4) - - 2 (0.9) 
Simvastatin 
(30mg) 
Generic  43 (18.9) - 7 (3.1) 1 (0.4) 51 (22.4) 
 Total 167 (73.2) 45 (19.7) 13 (5.7) 3 (1.3) 228 (100) 
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Figure 1: Potential cost savings (US$) per month from prescribing generic statins to the 228 
hypertensive patients with hypercholesterolemia between November 2011 to April 2012 
 
 
 
Discussion 
 
It was encouraging to see that simvastatin was prescribed exclusively as the generic version. Overall 
though originators were prescribed more often than generics, despite generics being available for 
each statin (Table 2), which is a concern.. The appreciable prescribing of originators may be due to 
several factors. These include SUHVFULEHUV¶NQRZOHGJHabout generics as well as concerns with their 
effectiveness and safety in routine clinical care including locally produced generics [37]. This will be 
the subject of future research given the opportunity for considerable savings (Figure 1). 
 
The appreciable prescribing of both originator atorvastatin and rosuvastatin drove up the monthly cost 
of statins (Table 3). As a result, there were appreciable opportunities for savings in Nigeria with 
increased prescribing and dispensing of generics for these two statins versus the originators (Table 4 
and Figure 1). Prescribing of generics instead of originators among all the statins except for 
simvastatin would have yielded 60% savings. 
 
The greater use of atorvastatin, principally as the originator (brand named medicine), compared with 
simvastatin may be due to the long length of time since patent expiration coupled with aggressive 
marketing [45]. Marketing activities may also account for the appreciable use of rosuvastatin (Table 
3). However, we cannot say this with certainty as the reasons behind the choice of statin and its 
presentation (originator or generic) was not explored in this research project. 
 
Strategies to increase the prescribing of generic versus originator statins include greater 
encouragement of INN prescribing in line with current regulations [32]. This could be achieved 
through a number initiatives including education of physicians regarding INN prescribing starting in 
medical school, regular benchmarking of physician prescribing habits and potentially financial 
incentives for physicians for greater prescribing of generics [22, 46]. Such measures have achieved 
98% to 99% INN prescribing in the UK for cardiovascular medicines including renin-angiotensin 
inhibitors and statins [22], providing a goal for the authorities in Nigeria. Other measures could include 
substitution targets for pharmacists or mandatory generic substitution [23, 46]. However, physicians in 
Nigeria currently have concerns with generic substitution because of concerns with their quality 
including bioequivalence [37]. As a result there needs to be strategies to re-assure physicians about 
the quality of generics through for instance measures to ensure the instigation of good manufacturing 
practices for locally sourced and imported generics in Nigeria to meet the strict bioequivalence criteria 
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seen in Europe before they receive marketing authorisation [47]. These strategies are important to 
ensure that patients receive the full health benefit from generic medicines including generic statins. 
 
The prescribed daily doses of statins were lower than the DDD (Table 2) especially for simvastatin 
with only 8 patients prescribed the DDD or above (Table 2). Only six out of the 51 patients prescribed 
40mg simvastatin (Table 2), which is the recommended dose in Scotland for patients with heart 
disease and diabetes [22] . Strategies to address this include greater education among physicians as 
well as potentially monitoring lipid levels in practice. These combined activities, together with financial 
incentives for physicians, led to increased prescribing of higher strength statins in the UK [22, 48]. 
 
Finally, the costs of generic statins appear to be appreciably higher in Nigeria that seen in for instance 
Netherlands, Sweden or the UK (Table 4). In these countries, monthly costs of 20 to 40mg generic 
simvastatin are approximately US$2 to US$5/ month [22-24]. These differences could be explained by 
WKHµRSHQPDUNHW¶SROLF\IRUSKDUPDFHXWLFDOVLQ1LJHULDZLWKFXUUHQWO\QRDWWHPSWWRUHJXODWHWKHSULFHV
of pharmaceuticals. Obtaining lower costs for statins through some form of government intervention 
will generate additional savings for patients and the healthcare system, building on those already 
outlined (Figure 1). Potential interventions could be in the form of tax breaks, reductions in import 
duties as well as requesting greater transparency in the pricing of pharmaceuticals including generics. 
As a result, potentially more patients will be able to comply with their prescriptions given the chronic 
nature of cardiovascular disease. 
 
We are aware that there are a number of limitations with this study. Firstly, only 228 patients were 
enrolled. In addition, we only concentrated on three clinics at UCH in Ibadan, Nigeria. We were also 
not able to obtain costing data for from hospital pharmacists for all statins prescribed. This was the 
case for fluvastatin but not the other statins. Lastly, we did not explore the reasons behind the 
prescribing of originators versus generics or the reasons behind the doses of statins prescribed. 
Never-the-less, we feel this is a valid study suggesting considerable opportunities to improve the 
quality and efficiency of statin prescribing in the future. This includes lowering OOP for patients 
reducing the financial burden of chronic cardiovascular diseases. We will be exploring these issues in 
future research projects including potential strategies to obtain lower prices for generics in Nigeria 
similar to the situation in the Netherlands, Sweden and the UK. 
 
Conclusion 
 
We have shown that there are considerable opportunities to improve both the quality and efficiency of 
statin prescribing in Nigeria through increasing the doses of statin prescribed as well as encouraging 
increased prescribing of generics. There are also potential opportunities to obtain lower prices of 
generics. These will be the subject of further research projects. 
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Executive Summary 
 
x Statins are first line treatment for patients with hypercholesterolemia to reduce future cardiac 
event rates 
x In patients with hypertension, they also reduce blood pressure, enhancing their role in patients 
with cardiovascular disease 
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x All statins are seen as essentially similar at therapeutic doses, with no published difference in the 
effectiveness between generics and originators. Generic statins are also considerably cheaper 
than originators or patented statins in a class 
x There was appreciable use of originator versus generic statins in Nigeria despite high out-of-
pocket payments. In addition, prescribed doses of statins were generally sub-optimal (based in 
defined daily doses) 
x (GXFDWLRQDOLQLWLDWLYHVDUHQHHGHGWRLQFUHDVHWKHGRVHVRIVWDWLQVSUHVFULEHGWRUHGXFHSDWLHQWV¶
risks of developing or progressive their cardiovascular disease. Increased prescribing of generic 
statins will benefit both patients and the healthcare system.  
x There are opportunities to further lower prices of generic statins in Nigeria towards those seen 
among some European countries. As a result, save further expenditure for the healthcare system 
and patients  
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